Delivery Method: Via Electronic Mail – Delivery and Read Receipt Requested Product: Drugs Recipient: Recipient Name Mr. Mark L’Hommedieu Recipient Title Managing Partner ProRx, LLC 619 […]

Reference #: FEI 3009728473 Product: Drugs Recipient: Recipient Name Amanda Biggart and Dakota Flowers Recipient Title Chief Operating Officer/Compliance Manager Safe Chain Solutions, LLC 822 Chesapeake […]

Delivery Method: Via Email Product: Drugs Recipient: Recipient Name Mr. Charles D. Boyd Recipient Title Founder and Chief Executive Officer Safe Chain Solutions, LLC 822 Chesapeake […]

To facilitate Biological Product Deviation (BPD) reporting, FDA has developed a standardized reporting form that may be submitted electronically via e-mail or in paper format by […]

[12-19-2017 ] La Administración de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en inglés) está requiriendo una nueva clase de advertencia y otras […]

[12-19-2017 ] The U.S. Food and Drug Administration (FDA) is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for […]

[12-16-2016] Based on a U.S. Food and Drug Administration (FDA) review of a large clinical trial that we required the drug companies to conduct,1 we have […]

For Immediate Release: March 14, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Thursday, […]

Update [7/27/2018] On July 13th, FDA announced a recall of certain batches of valsartan tablets because of an impurity, a chemical known as N-nitrosodimethylamine (NDMA). Valsartan […]